Fluid levels to prevent lung disease in preterm babies
Part of Genetic & congenital, Lungs & breathing clinical trials.
This trial compares giving less fluid versus the usual amount to very early preterm babies to see if it helps prevent bronchopulmonary dysplasia, a chronic lung condition. The goal is to find the safest way to manage fluids and protect their developing lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Born before 30 weeks of pregnancy (30 weeks 0 days)
- Currently hospitalized in a neonatal intensive care unit
- Parents or guardians have signed consent for research use of health data
- No major birth defects or serious health problems that affect the lungs, kidneys, or brain
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving intravenous immunoglobulin (IVIG) early after birth can help prevent or treat a serious lung condition called bronchopulmonary dysplasia (BPD) in babies born at 28 weeks or earlier. It may help reduce the need for breathing support and oxygen.
This study tests a new way of setting the ventilator for preterm babies born before 34 weeks who are still on a breathing machine. It aims to improve lung healing and heart function by finding the best pressure settings. The results could help your baby breathe more comfortably.
This Phase 1 trial tests whether giving stem cells into a breathing tube is safe and may help prevent bronchopulmonary dysplasia (BPD), a serious lung condition in very premature infants. It focuses on babies soon after birth who already need breathing support and are at risk.
This study is testing whether a simple ultrasound of the lungs done right after birth can help predict a lung problem called bronchopulmonary dysplasia (BPD) in very early preterm babies. If successful, this could help doctors identify babies at high risk sooner and provide better care.
This trial tests a medicine called zelpultide alfa in very premature babies who are at high risk of developing bronchopulmonary dysplasia (BPD), a chronic lung disease. The goal is to see if it can help prevent or lessen lung problems compared to standard care alone.
This study looks at very premature babies (born before 26 weeks) to find early signs that might predict a lung condition called bronchopulmonary dysplasia. The goal is to help doctors identify which babies are at risk sooner, so they can provide better care.
Hear when a new Bronchopulmonary Dysplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.